Navigation Links
Tengion Presents New Data in Nine Posters and Two Oral Presentations at TERMIS North America Annual Meeting
Date:12/7/2010

a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. An initial clinical trial is ongoing for the Company's lead product candidate, the Neo-Urinary Conduit™, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal.  The Company's lead preclinical program is the Neo-Kidney Augment™, which is designed to delay or prevent the need for dialysis or transplantation in patients at risk for kidney failure.  Tengion has also applied its technology in two Phase II clinical trials for Tengion's Neo-Bladder Augment™ for the treatment of neurogenic bladder.  Tengion has worldwide rights to its product candidates. For more information, please visit www.tengion.com.

Forward-Looking Statements

Certain statements set forth above may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to the Company's: (i) plans to develop and commercialize its product candidates, including the Neo- Kidney Augment and the Neo-Urinary Conduit; and (ii) expectations regarding ongoing and planned preclinical studies and clinical trials. Although Tengion believes that these statements are based upon reasonable assumptions within the bounds of its knowledge of its business and operations, there are a number of factors that may cause actual results to differ from these statements. For instance there can be no assurance that: (i) the Company will be able to obtain the capital it needs to develop its product candidates or continue as a going concern; (ii) the Company will be able to successfully enroll patients in its clinical trials, including its Phase I clinical trial for the Neo-Urinary Conduit; (iii) patients enrolled in the Company's clinical t
'/>"/>

SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
2. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
3. Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)
4. Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration Vs. Repair
5. Tengion Appoints Sunita B. Sheth, M.D., Chief Medical Officer
6. Tengion Presents New Data Demonstrating Functional Regeneration in a Diabetic Chronic Kidney Failure Model at the International Society for Cellular Therapy
7. Tengion Announces First Implantation of Neo-Urinary Conduit™ in Initial Clinical Trial in Patients with Bladder Cancer
8. Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs
9. Tengion Provides Business Update and Reports Third Quarter 2010 Financial Results
10. Tengion Advances Clinical Trial for Neo-Urinary Conduit™ in Bladder Cancer Patients
11. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015 /CNW/ - Covalon Technologies Ltd. ... technologies company, today announced financial results for its first ... the three months ended December 31, 2014, revenue was ... quarter was $229,820 or $0.02 per share.  ... said "I am very pleased with the significant progress ...
(Date:2/27/2015)...  Uroplasty, Inc. (NASDAQ: UPI ), a medical ... products to treat voiding dysfunctions, today announced that it ... Tuesday, March 10, 2015. Rob Kill , President ... Officer, will present at 4:00 p.m. Pacific Time and ... at the Ritz Carlton in Laguna Niguel, ...
(Date:2/26/2015)... , Feb. 27, 2015  Finesse expands office in ... Finesse Solutions announced the expansion of its operations in ... planned for mid-March and access for customers is expected ... A-563, and located adjacent to the current office, the ... Finesse automation engineering team and allow Finesse to bring on ...
Breaking Medicine Technology:Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3Uroplasty to Participate in the 27th Annual ROTH Conference 2New Finesse Office in United Kingdom 2
... , PLYMOUTH MEETING, Pa., Nov. 20 ... article that questions why currently available medications designed to treat and ... organization, is offering a roadmap to the evidence on Finasteride ... , The November 13, 2009, New York Times article, ...
... , PRINCETON, N.J., Nov. 20 Soligenix, ... formerly known as DOR BioPharma, Inc., a late-stage biotechnology ... to develop thermostable technology to advance RiVax(TM) and other ... from the National Institute of Allergy and Infectious Diseases ...
Cached Medicine Technology:ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 2ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 4Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 5Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 6
(Date:3/2/2015)... TX (PRWEB) March 02, 2015 What ... How should physicians request references? When are interviews scheduled, ... analyze employment opportunities?, Both training and practicing physicians who ... to these questions and more at the PracticeLink Physician ... 18. The drop-in Job Fair is from 5:30 to ...
(Date:3/2/2015)... ProvidaStaff has announced today that it is changing ... EDU Healthcare to reflect better on the commitment ... nationwide. , “ProvidaStaff has always been a leading healthcare ... Angela M. Lewis, President of ProvidaStaff. “We continue to ... of EDU Healthcare better aligns our services to our ...
(Date:3/2/2015)... 02, 2015 Secura Consultants announced ... with First Protective Insurance Group of Birmingham, AL ... First Protective affiliated advisors to access the enhanced ... Secura Consultants delivers. , Secura Consultants, ... in the design and implementation of insured income ...
(Date:3/1/2015)... 2015 As residents and business ... Michael Burns and Carita Weaver, believe in supporting ... with the Southlake Chamber of Commerce, Carroll Independent ... recently launched a website for Southlake mayoral candidate ... communications tool for Hill’s campaign, the website combines ...
(Date:3/1/2015)... 01, 2015 Comparing a new source ... using the Quotes Pros portal this year. A broad ... insurance rates that are being supplied through the finder ... agencies and prices available for each policy is now ... Every system user will first be asked to present ...
Breaking Medicine News(10 mins):Health News:PracticeLink to Host a Career Advancement Workshop and Job Fair in Houston 2Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 2Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 3Health News:Secura Consultants and First Protective Insurance Group Announce Strategic Relationship 2Health News:Website Launched for Southlake, Texas Mayoral Candidate Laura Hill 2Health News:United Auto Insurance Rates Now Quoted at Consumer Insurance Portal Online 2
... families are involved, study finds , FRIDAY, June 12 ... of an incurable genetic disease isn,t worry enough, people ... discriminated against by insurance companies, relatives and in social ... and colleagues at the University of British Columbia surveyed ...
... , ATLANTA, June 12 Salient Mobility LLC, ... of the 2009 " Text For a Cause(TM) " campaign, ... from organizations such as the Georgia Cancer Foundation . ... campaign begins August 24th, and culminates with the issuance of ...
... 12 June 2009: Three new studies have individually shown ... effective, with a good safety profile, in children under ... and associated with improved Health-Related Quality of Life (HRQoL) ... data are being presented at the Paediatric Rheumatology European ...
... five years of receiving infliximab (IFX) anti-TNF therapy, 61.8% ... benefit (ASAS40, ASsessment in AS, 40-response) and 27.6% achieved ... AS patients had no arthritis and 84.9% had no ... Over this period, patients continued to show a sustained ...
... National Quality Forum (NQF) has tapped Thomas B. Valuck, ... Strategic Partnerships. Dr. Valuck comes to NQF from the ... was both Medical Officer and Senior Adviser in the ... a unique, multi-stakeholder, nonprofit organization dedicated to improving the ...
... Medifast, Inc. (NYSE: MED ) today announced ... corporate-owned Medifast Weight Control Centers. Earlier in the year, the ... out, and analyze the success of the model throughout the ... be expanding its investment in this area. , , ...
Cached Medicine News:Health News:People With Huntington's Report Discrimination 2Health News:People With Huntington's Report Discrimination 3Health News:Salient Mobility Launches the 'Text For a Cause(TM)' Campaign in Raising Awareness Through Wireless Health Tips 2Health News:3 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritis 2Health News:3 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritis 3Health News:3 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritis 4Health News:IFX anti-TNF therapy associated with clinical benefit over 5 years in patients with active AS 2Health News:IFX anti-TNF therapy associated with clinical benefit over 5 years in patients with active AS 3Health News:National Quality Forum Welcomes Dr. Thomas Valuck, SVP of Strategic Partnerships 2Health News:National Quality Forum Welcomes Dr. Thomas Valuck, SVP of Strategic Partnerships 3Health News:Medifast, Inc. to Expand Investment in Corporate Medifast Weight Control Centers 2Health News:Medifast, Inc. to Expand Investment in Corporate Medifast Weight Control Centers 3
Pre-set guard for precise depth incision, bi-directional blade can cut left or right. 250 micron....
...
...
... a cutting-edge ECG management system ... and convenient, web-based access to ... information technology (IT) benefits, resulting ... and improved patient care. ...
Medicine Products: